X

Johnson & Johnson (JNJ) Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release

Newsdesk: